附件 99.2

Lipella 製藥公司宣佈完成200萬美元的私募，根據納斯達克規則按市場定價

匹茲堡，賓夕法尼亞州，2023年10月25日-Lipella PharmPharmticals Inc.(“Lipella”，“Our”，“US”或“公司”)，一家臨牀階段的生物技術公司，致力於解決具有重大未得到滿足的需求的嚴重疾病，今天宣佈結束其先前宣佈的私募交易，根據納斯達克規則按市場定價，購買和出售預先融資的認股權證，以購買總計1,315,790股和認股權證，購買總計1,315,790股。每份預付資助權證及附屬認股權證的買入價為1.519美元。

H.C. Wainwright&Co.擔任此次發行的獨家配售代理。

認股權證的行使價為每股1.40美元，可在發行時立即行使，有效期為自發行之日起三年。

在扣除配售代理費和公司應支付的其他發售費用之前，理柏的私募所得毛收入約為200萬美元。本公司擬將所得款項淨額用作營運資金及一般公司用途。

上述證券的發售和出售是根據經修訂的1933年證券法第4(A)(2)節(“該法案”)及據此頒佈的條例D以私募方式發售的，而該等證券連同認股權證及預先出資認股權證所涉及的普通股股份並未根據該法案或適用的州證券法登記。因此，私募發行的證券以及認股權證和預融資認股權證相關的普通股股票不得在美國發行或出售，除非有有效的註冊聲明或適用的豁免，使其不受該法和相關州證券法的註冊要求的約束。

該公司已同意向美國證券交易委員會(“美國證券交易委員會”)提交一份初步註冊聲明，內容包括認股權證和預籌資權證所涉及的普通股股份的轉售，不遲於相關最終協議之日起7個工作日內，並在美國證券交易委員會進行“全面審查”的情況下，不遲於相關最終協議之日起75天內宣佈註冊聲明生效。

本新聞稿不構成出售或邀請購買本文所述任何證券的要約，也不會在任何州或其他司法管轄區出售這些證券，在這些州或其他司法管轄區，此類要約、招攬或出售在根據任何此類州或其他司法管轄區的證券法註冊或資格之前將是非法的。

關於利佩拉制藥公司

Lipella 是一家臨牀階段的生物技術公司，專注於通過重新配製現有仿製藥中的活性成分並針對新的應用優化這些重新配方來開發新藥。此外，Lipella的治療重點是那些目前還沒有得到批准的藥物療法的重大、未解決的發病率和死亡率的疾病。Lipella於2022年12月完成首次公開募股(IPO)。欲瞭解更多信息，請訪問www.lipella.com或LinkedIn。

前瞻性陳述

This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, the use of net proceeds from the private placement, as well as our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to the effective application of the use of proceeds from the private placement, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.

接觸

首席執行官喬納森·考夫曼博士

利培拉藥品

郵箱：Info@Lipella.com

1-412-894-1853

Jeff 拉姆森

PCG 諮詢

郵箱：jramson@pcgvisory.com